Article
HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association - 1 Feb 1997
Demeter L M, Meehan P M, Morse G, Gerondelis P, Dexter A, Berrios L, Cox S, Freimuth W, Reichman R C
Abstract excerpt
Previous studies have shown that the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase mutation Y181C, which confers high-level resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs), develops rarely during therapy with NNRTIs plus zidovudine. To determine whether d...
Topics
- Adult
- Anti-HIV Agents
- Delavirdine
- Didanosine
- Drug Resistance, Microbial
- Drug Therapy, Combination
- Female
- HIV Infections
- HIV Reverse Transcriptase
- HIV-1
- Humans
- Indoles
- Male
- Mutation